Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: phase 1 final analysis

Toshiki Uchida

Presentation information

Oral Session

Oral Session 1-8D Malignant Lymphoma: Clinical studies

Fri. Oct 12, 2018 4:20 PM - 5:20 PM No.8 (Osaka International Convention Center, 10F 1002)

Chair: Koji Izutsu (National Cancer Center Hospital, Japan)

[OS1-8D-3] Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: phase 1 final analysis

Toshiki Uchida¹, Kensei Tobinai², Noriko Fukuhara³, Wataru Munakata², Shinichi Makita², Miki Kobayashi¹, Shigeki Saito¹, Yohei Yamaguchi¹, Tomoaki Nishikawa⁴ (1.Japanese Red Cross Nagoya Daini Hosp., Nagoya, Japan, 2.National Cancer Ctr. Hosp., Tokyo, Japan, 3.Tohoku Univ. Hosp., Sendai, Japan, 4.Janssen Pharmaceutical K.K., Tokyo, Japan)

Abstract password authentication.
Password is written on a program and abstract book.